NCT05265078View on ClinicalTrials.gov

A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

CompletedOBSERVATIONAL
Enrollment

102

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
Von Willebrand Disease (VWD)
Trial Locations (1)

61352

MVZ Gerinnungszentrum Hochtaunus, Bad Homburg

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT05265078 - A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi | Biotech Hunter | Biotech Hunter